Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZTOJ6)

Drug Name

TBA-7371 Drug Info

Synonyms

1494675-86-3; DprE1-IN-1; AZ7371; N-(2-hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide; UNII-R3T98GBE3C; AZ-7371; R3T98GBE3C; CHEMBL3109802; 1H-Pyrrolo(3,2-b)pyridine-3-carboxamide, N-(2-hydroxyethyl)-1-((6-methoxy-5-methyl-4-pyrimidinyl)methyl)-6-methyl-; 1H-Pyrrolo[3,2-b]pyridine-3-carboxamide, N-(2-hydroxyethyl)-1-[(6-methoxy-5-methyl-4-pyrimidinyl)methyl]-6-methyl-; ZA7371; AZ-7371DprE1-IN-1; AZ7371;DprE1-IN-1; SCHEMBL16395186; EX-A777; BCP16818; BDBM50019654; MFCD29477419; ZINC103248024; CS-5414; ZA-7371; HY-19750; FT-0700212; J-690193; N-(2-Hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6- methyl-1H-pyrrolo(3,2-b)pyridine-3-carboxamide; N-(2-hydroxyethyl)-1-[(6-methoxy-5-methyl-pyrimidin-4-yl)methyl]-6-methyl-pyrrolo[3,2-b]pyridine-3-carboxamide; N-(2-hydroxyethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-6-methylpyrrolo[3,2-b]pyridine-3-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Tuberculosis	1B10-1B14	Phase 2	[1]

Cross-matching ID

PubChem CID: 72792692
CAS Number: CAS 1494675-86-3
TTD Drug ID: DMZTOJ6

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BTZ-043	DMVXBSW	Tuberculosis	1B10-1B14	Phase 2	[3]
OPC-167832	DMZB6LO	Tuberculosis	1B10-1B14	Phase 1/2	[4]
Macozinone	DM0HKU7	Mycobacterium infection	1B10-1B21	Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)	TTLOHU4	DPRE1_MYCTU	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03199339) A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of TB Alliance.
3	Clinical pipeline report, company report or official report of TB
4	OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.
5	Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties. ACS Med Chem Lett. 2019 Feb 23;10(3):348-351.